Placebo will consist of a normal saline (0.9% NaCl) solution and will be administered in 100 mL or 250 mL infusion bags clinical trials

A Phase 3b/4, Double-masked, Randomized, International, Parallel-assignment, Multicenter Trial in Patients with Thyroid Eye Disease to Evaluate the Safety and Tolerability of Different Dosing Durations of Teprotumumab

This study is looking at a new treatment called teprotumumab for Thyroid Eye Disease. It aims to safely see if different lengths of taking the medicine affect how well it works and if people need further treatment later.